Mini-symposia Topics

Controlled Release in Consumer and Diversified Products: Changes in Industry Regulations and Industrial Applications

‘In Vitro’ Absorption Guidelines for Cosmetic Ingredients
Nava Dayan, Lipo Chemicals Inc., U.S.A.

Durable Microcapsules for Non-Release Applications
Mark Hartmann, Outlast Technologies, Inc., U.S.A.
Lyn Hughes, Rohm and Haas, U.S.A.

Cosmeceutical Skin Care Products – Current Regulatory Affairs
Wen Schroeder, SEKI Cosmeticals, LLC, U.S.A.

Enhancing Drug Delivery – Using Novel Animal Models

Chick Embryo Chorioallantoic Membrane (CAM) for the Evaluation of Drug Delivery Systems
Florence Delie-Salmon, University of Geneva, Switzerland

Animal Models for Drug Delivery Across Airway Mucosal Barriers
Lucila Garcia-Contreras, University of North Carolina, U.S.A.

Animal Models in Drug Delivery: Indispensables, Limitations and Alternatives
Kinam Park, Purdue University, U.S.A.

Comparative Species Differences in Dermal Absorption: Exploiting the Similarities and Differences for Veterinary and Human Health Applications
Jim E. Riviere, North Carolina State University, U.S.A.

Global Health

Translating Technology to Improve Global Health
Nicola Bailey, The Wellcome Trust, U.K.

Targeted Delivery of Anti-TB Drugs and Vaccines Formulated as Spray-Dried Powders
Bernard Fourie, Medicines in Need, South Africa

Drug Delivery Challenges Facing Big Pharma
L. Gino Martini, GlaxoSmithKline, U.K.

Inventive Academics Can Make New Pharmaceuticals for Global Use
Sunil Shaunak, Imperial College London, U.K.

Innovation in Nanomaterial Synthesis & Fabrication

Acid-Labile Phase Transition Polymers for DNA Delivery
Cameron Alexander, University of Nottingham, U.K.

Supramolecular Mesoporous Materials for Controlled Release and Separation: Carbon Nanocage and Nanocompartment Film
Katsuhiko Ariga, National Institute for Materials Science, Japan

Immunolipopolyplex Nanoparticals of ODN and siRNA for Targeted Leukemia Therapy
L. James Lee, Ohio State University, U.S.A.

Reservoir Arrays for Drug Delivery
Elizabeth Proos, MicroCHIPS, Inc., U.S.A.

Mental and Neurological Health

Route of Administration and Formulation of Naltrexone Influence Non-Clinical Pharmacodynamic End-Points and Clinical Pharmacokinetics
Daniel R. Deaver, Alkermes, Inc., U.S.A.

Sustained Release Naltrexone for the Treatment of Alcohol Dependence
Stephanie O’Malley, Yale University School of Medicine, U.S.A.

Dinah Sah, Alnylam Pharmaceuticals, U.S.A.

Obesity and Metabolic Diseases

Exenatide Treatment of Type 2 Diabetes: Development Path and Outcomes from Immediate and Long Acting Formulations
Mark Fineman, Amylin Pharmaceuticals, Inc., U.S.A.

Insulin Formulation and Delivery - A Never-ending Challenge
Liselotte Langkjaer, Novo Nordisk A/S, Denmark

In Pursuit of Closed Loop Delivery of Insulin
M. Joan Taylor, De Montfort University-Leicester, U.K.

Anti-Obesity Agents Based on Galengine
Roger Waigh, University of Strathclyde, Scotland